CA1306581C - Platelet binding inhibitors - Google Patents
Platelet binding inhibitorsInfo
- Publication number
- CA1306581C CA1306581C CA000521502A CA521502A CA1306581C CA 1306581 C CA1306581 C CA 1306581C CA 000521502 A CA000521502 A CA 000521502A CA 521502 A CA521502 A CA 521502A CA 1306581 C CA1306581 C CA 1306581C
- Authority
- CA
- Canada
- Prior art keywords
- arg
- peptide
- lys
- formula
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000027455 binding Effects 0.000 title claims abstract description 24
- 239000003112 inhibitor Substances 0.000 title abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 88
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 22
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 13
- 108010049003 Fibrinogen Proteins 0.000 claims description 20
- 102000008946 Fibrinogen Human genes 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 230000002776 aggregation Effects 0.000 claims description 12
- 238000004220 aggregation Methods 0.000 claims description 12
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 29
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 4
- 230000021164 cell adhesion Effects 0.000 abstract description 2
- 210000001772 blood platelet Anatomy 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000011575 calcium Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 3
- 101100495256 Caenorhabditis elegans mat-3 gene Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000001875 compounds Chemical group 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- STSKWZSBFZRSGP-GYDGUXFESA-N (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]acetyl]amino]propanoyl]amino]he Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1NC=NC=1)C1=CN=CN1 STSKWZSBFZRSGP-GYDGUXFESA-N 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 2
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108010017446 glycyl-prolyl-arginyl-proline Proteins 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WXPZDDCNKXMOMC-AVGNSLFASA-N (2s)-1-[(2s)-2-[[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@H](C(O)=O)CCC1 WXPZDDCNKXMOMC-AVGNSLFASA-N 0.000 description 1
- RGNVSYKVCGAEHK-GUBZILKMSA-N (3s)-3-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O RGNVSYKVCGAEHK-GUBZILKMSA-N 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 108010034892 glycyl-arginyl-glycyl-aspartyl-serine Proteins 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US791,872 | 1985-10-28 | ||
| US06/791,872 US4683291A (en) | 1985-10-28 | 1985-10-28 | Platelet binding inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1306581C true CA1306581C (en) | 1992-08-18 |
Family
ID=25155042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000521502A Expired - Fee Related CA1306581C (en) | 1985-10-28 | 1986-10-27 | Platelet binding inhibitors |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US4683291A (enExample) |
| EP (1) | EP0220957A3 (enExample) |
| JP (1) | JPS62161800A (enExample) |
| CA (1) | CA1306581C (enExample) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041380A (en) * | 1982-08-04 | 1991-08-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
| US20030143733A1 (en) * | 1985-06-17 | 2003-07-31 | La Jolla Cancer Research Foundation | Tetrapeptide |
| IT1190433B (it) * | 1985-12-11 | 1988-02-16 | Prodotti Antibiotici Spa | Peptidi correlati al lisozima |
| US5238919A (en) * | 1986-05-30 | 1993-08-24 | Scipps Clinic And Research Foundation | Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor |
| US5352664A (en) * | 1986-10-31 | 1994-10-04 | Board Of Regents, The University Of Texas System | Thrombin derived polypeptides; compositions and methods for use |
| US6630572B1 (en) | 1986-10-31 | 2003-10-07 | The Board Of Regents, University Of Texas Syatems | Thrombin derived polypeptides: compositions and methods for use |
| DE3781263T2 (de) * | 1986-12-15 | 1993-04-08 | Inst Nat Sante Rech Med | Peptid-derivate und deren verwendung in der therapie. |
| FR2617169B1 (fr) * | 1987-06-25 | 1991-09-20 | Inst Nat Sante Rech Med | Nouveaux derives peptidiques et leur application notamment en therapeutique |
| US5043429B1 (en) * | 1987-05-01 | 1997-10-14 | Scripps Research Inst | Protein fragments containing factor VIII binding domain of von willebrand factor |
| FR2617170B1 (fr) * | 1987-06-25 | 1989-12-22 | Inst Nat Sante Rech Med | Nouveaux derives peptidiques et leur application notamment en therapeutique |
| FR2622587B1 (fr) * | 1987-10-30 | 1990-12-21 | Inst Vaisseaux Sang | Peptide lysyl-arginyl-aspartyl-serine et ses applications en tant que medicament, notamment antithrombotique |
| US5340727A (en) * | 1987-11-17 | 1994-08-23 | The Scripps Research Institute | GPIbα fragments and recombinant DNA expression vectors |
| US4857508A (en) * | 1987-12-03 | 1989-08-15 | Monsanto Company | Novel platelet-aggregation inhibitor peptide derivatives |
| AU639409B2 (en) * | 1987-12-10 | 1993-07-29 | La Jolla Cancer Research Foundation | Conformationally stabilized cell adhesion peptides |
| US5827821A (en) * | 1987-12-10 | 1998-10-27 | The Burnham Institute | Conformationally stabilized cell adhesion peptides |
| US5256559A (en) * | 1988-03-04 | 1993-10-26 | Biogen, Inc. | Methods and compositions for inhibiting platelet aggregation |
| US5066592A (en) * | 1988-03-08 | 1991-11-19 | Temple University Of The Commonwealth System Of Higher Education | Trigramin - a platelet aggregation inhibiting polypeptide |
| AU3149289A (en) * | 1988-03-18 | 1989-09-21 | Rockefeller University, The | Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor |
| NZ228710A (en) * | 1988-04-22 | 1992-10-28 | Merck & Co Inc | Modified "echistatin" and anti-clotting pharmaceutical composition |
| JPH03505087A (ja) * | 1988-04-29 | 1991-11-07 | ニュー イングランド ディーコネス ホスピタル コーポレイション | ハイブリッドペプチド及びその使用方法 |
| DE3814911A1 (de) | 1988-05-03 | 1989-11-16 | Jagenberg Ag | Vorrichtung zum ueberfuehren von flachen, ungleich dicken gegenstaenden zu einer packeinrichtung |
| ZW6189A1 (en) * | 1988-05-09 | 1990-05-09 | Smithkline Beckman Corp | Anti-aggregatory peptides |
| FR2631626B1 (fr) * | 1988-05-20 | 1990-08-10 | Centre Nat Rech Scient | Nouveaux pentapeptides et leurs applications en tant que medicaments, notamment antithrombotiques |
| US4992463A (en) * | 1988-07-20 | 1991-02-12 | Monsanto Company | Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation |
| US4879313A (en) * | 1988-07-20 | 1989-11-07 | Mosanto Company | Novel platelet-aggregation inhibitors |
| US5053393A (en) * | 1988-07-20 | 1991-10-01 | Monsanto Company | Novel platelet-aggregation inhibitor |
| US5091396A (en) * | 1988-07-20 | 1992-02-25 | Monsanto Co. | Pyridyl peptide mimetic compounds which are useful platelet-aggregation inhibitors |
| US5037808A (en) * | 1988-07-20 | 1991-08-06 | Monsanto Co. | Indolyl platelet-aggregation inhibitors |
| US5759855A (en) * | 1988-09-14 | 1998-06-02 | La Jolla Cancer Research Foundation | Methods for modifying the binding activity of cell adhesion receptors |
| ATE116548T1 (de) * | 1988-09-14 | 1995-01-15 | Jolla Cancer Res Found | Methode für die änderung der bindung eines zelladhäsionrezeptors. |
| AU4528589A (en) * | 1988-11-03 | 1990-05-28 | Prime Technology | A sheet feeding apparatus |
| US5169836A (en) * | 1988-11-10 | 1992-12-08 | Trustees Of The University Of Penna. | Inhibitors of platelet binding |
| JPH04503660A (ja) * | 1988-12-05 | 1992-07-02 | バイオジェン インコーポレイテッド | 血小板凝集抑制の方法及び組成物 |
| US5039805A (en) * | 1988-12-08 | 1991-08-13 | Hoffmann-La Roche Inc. | Novel benzoic and phenylacetic acid derivatives |
| US5654267A (en) * | 1988-12-20 | 1997-08-05 | La Jolla Cancer Research Center | Cooperative combinations of ligands contained within a matrix |
| ATE135584T1 (de) * | 1988-12-20 | 1996-04-15 | Jolla Cancer Res Found | Polypeptid-polymer-konjugate mit wundheilender wirkung |
| US5196510A (en) * | 1988-12-29 | 1993-03-23 | Cytogen Corporation | Molecular recognition units |
| US5196403A (en) * | 1989-01-27 | 1993-03-23 | Biogen, Inc. | Method of inhibiting platelet activation |
| US5182260A (en) * | 1989-01-27 | 1993-01-26 | Biogen, Inc. | Dna sequences encoding snake venom inhibitors of platelet activation processes for producing those inhibitors and compositions using them |
| CA2008116C (en) * | 1989-02-23 | 2001-11-20 | Thomas Weller | Glycine derivatives |
| JP2878341B2 (ja) * | 1989-03-03 | 1999-04-05 | 学校法人藤田学園 | 人工機能性ポリペプチド |
| US5120829A (en) * | 1989-03-20 | 1992-06-09 | La Jolla Cancer Research Foundation | Hydrophobic attachment site for adhesion peptides |
| AU5939890A (en) * | 1989-06-07 | 1991-01-07 | Genentech Inc. | Platelet aggregation inhibitors and related molecules |
| US5686568A (en) * | 1989-06-16 | 1997-11-11 | Cor Therapeutics, Inc. | Platelet aggregration inhibitors |
| US5780595A (en) * | 1989-06-16 | 1998-07-14 | Cor Therapeutics, Inc. | Platelet aggregation inhibitors |
| GB8914020D0 (en) † | 1989-06-19 | 1989-08-09 | Antisoma Ltd | Synthetic peptides for use in thrombus detection |
| US5395609A (en) * | 1989-06-19 | 1995-03-07 | Antisoma Limited | Synthetic peptides for use in tumor detection |
| US5320945A (en) * | 1989-07-14 | 1994-06-14 | Boehringer Mannheim Gmbh | Method and reagent for the determination of antithrombin III |
| US5384309A (en) * | 1989-07-17 | 1995-01-24 | Genentech, Inc. | Cyclized peptides and their use as platelet aggregation inhibitors |
| US5061693A (en) * | 1989-07-28 | 1991-10-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5023233A (en) * | 1989-07-28 | 1991-06-11 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5120859A (en) * | 1989-09-22 | 1992-06-09 | Genentech, Inc. | Chimeric amino acid analogues |
| US4952562A (en) * | 1989-09-29 | 1990-08-28 | Rorer Pharmaceutical Corporation | Anti-thrombotic peptides and pseudopeptides |
| US5332726A (en) * | 1989-09-29 | 1994-07-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Antithrombotic peptides and pseudopeptides |
| US5051405A (en) * | 1989-10-10 | 1991-09-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Anti-thrombotic peptides and pseudopeptides |
| US5643872A (en) * | 1989-10-23 | 1997-07-01 | Smithkline Beecham Corporation | Cyclic anti-aggregatory peptides |
| CA2027936C (en) | 1989-10-23 | 2001-07-24 | Smithkline Beecham Corporation | Cyclic anti-aggregatory peptides |
| US5053392A (en) * | 1989-12-01 | 1991-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors |
| US5227469A (en) * | 1990-02-14 | 1993-07-13 | Genentech, Inc. | Platelet aggregation inhibitors from the leech |
| US5273982A (en) * | 1990-03-09 | 1993-12-28 | Hoffmann-La Roche Inc. | Acetic acid derivatives |
| US5428020A (en) * | 1990-03-23 | 1995-06-27 | Rei Matsueda | Cysteine (NPYS)-containing peptides and use thereof for inhibiting platelet aggregation |
| DE4009506A1 (de) * | 1990-03-24 | 1991-09-26 | Hoechst Ag | Hydantoinderivate |
| US5064814A (en) * | 1990-04-05 | 1991-11-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Anti-thrombotic peptide and pseudopeptide derivatives |
| US6521594B1 (en) | 1990-04-06 | 2003-02-18 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
| US5780303A (en) * | 1990-04-06 | 1998-07-14 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
| US5672585A (en) * | 1990-04-06 | 1997-09-30 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
| US5648330A (en) * | 1990-04-06 | 1997-07-15 | La Jolla Cancer Research Foundation | Method and composition for treating vascular graft occlusion |
| EP0749979A3 (en) * | 1990-04-06 | 1998-03-11 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
| US5612311A (en) * | 1990-04-06 | 1997-03-18 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
| JPH06502541A (ja) * | 1990-10-17 | 1994-03-24 | ザ スクリップス リサーチ インスティテュート | フォン・ウィルブランド因子の治療断片 |
| US5298488A (en) * | 1990-10-26 | 1994-03-29 | Fuji Photo Film Co., Ltd. | CM-chitin derivatives and use thereof |
| WO1992008476A1 (en) * | 1990-11-07 | 1992-05-29 | The Scripps Research Institute | Peptides that inhibit platelet binding of adhesion molecules |
| US5242810A (en) * | 1990-12-07 | 1993-09-07 | Biogen, Inc. | Bifunctional inhibitors of thrombin and platelet activation |
| US5652211A (en) * | 1991-02-11 | 1997-07-29 | Biosynth S.R.L. | Peptides for neutralizing the toxicity of Lipid A |
| KR100210206B1 (ko) * | 1991-03-06 | 1999-07-15 | 윌리암스 로저 에이 | 혈소판 응집 억제제로서 유용한 페닐아미딘 유도체 |
| US5492894A (en) * | 1991-03-21 | 1996-02-20 | The Procter & Gamble Company | Compositions for treating wrinkles comprising a peptide |
| CA2106314A1 (en) * | 1991-04-05 | 1992-10-06 | John P. Burnier | Platelet aggregation inhibitors having high specification for gpiibiiia |
| US5220050A (en) * | 1991-05-17 | 1993-06-15 | G. D. Searle & Co. | Peptide mimetic compounds useful as platelet aggregation inhibitors |
| DE4126277A1 (de) * | 1991-08-08 | 1993-02-11 | Cassella Ag | Hydantoinderivate |
| US5317097A (en) * | 1991-10-07 | 1994-05-31 | The Research Foundation Of State University Of New York | Mutations in the gene encoding the α chain on platelet glycoprotein IB |
| US5298239A (en) * | 1991-10-07 | 1994-03-29 | The Research Foundation Of State University Of New York | Mutations rendering platelet glycoprotein IB α less reactive |
| US5239113A (en) * | 1991-10-15 | 1993-08-24 | Monsanto Company | Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof |
| US5254573A (en) * | 1991-10-15 | 1993-10-19 | Monsanto Company | Substituted heterocyclic derivatives useful as platelet aggregation inhibitors |
| US5625093A (en) * | 1991-10-15 | 1997-04-29 | G. D. Searle & Co. | Substituted β-amino acid derivatives useful as platelet aggregation inhibitors |
| WO1993012103A1 (en) * | 1991-12-13 | 1993-06-24 | G.D. Searle & Co. | Phenyl amidines lactones useful as platelet aggregation inhibitors |
| US5424334A (en) * | 1991-12-19 | 1995-06-13 | G. D. Searle & Co. | Peptide mimetic compounds useful as platelet aggregation inhibitors |
| US5504106A (en) * | 1992-06-25 | 1996-04-02 | G. D. Searle & Co. | Phenyl amidine alkanoic acids and lactones useful as platelet aggregation inhibitors |
| US5338725A (en) * | 1992-06-30 | 1994-08-16 | The Research Foundation Of The State University Of New York | Anti-aggregatory agents for platelets |
| US5409939A (en) * | 1993-02-12 | 1995-04-25 | G. D. Searle & Co. | Phenyl amidine thio derivatives useful as platelet aggregation inhibitors |
| US5612355A (en) * | 1993-06-23 | 1997-03-18 | G. D. Searle & Co. | Phenyl amidine lactones useful as platelet aggregation inhibitors |
| FI961634A7 (fi) * | 1993-10-15 | 1996-05-23 | Rhone Poulenc Rorer Pharmaceuticals Inc | Antitromboottisia atsasykloalkyylialkanoyyli peptidejä ja pseudopeptid ejä |
| US5780590A (en) * | 1993-10-15 | 1998-07-14 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides |
| US6387880B1 (en) | 1994-10-24 | 2002-05-14 | G.D. Searle & Co. | Transdermal N-[N-[5-[4-(aminoiminomethly)phenyl]-1-oxopentyl]-L-α-aspartyl]-L-phenylalainine or its esters and their pharmaceutically acceptable salts |
| US5674894A (en) * | 1995-05-15 | 1997-10-07 | G.D. Searle & Co. | Amidine derivatives useful as platelet aggregation inhibitors and vasodilators |
| US7053041B1 (en) | 1996-05-31 | 2006-05-30 | The Scripps Research Institute | Methods and compositions useful for inhibition of αvβ5mediated angiogenesis |
| GB9519667D0 (en) * | 1995-09-27 | 1995-11-29 | Univ Manchester | Pharmaceutical composition |
| IL129877A (en) * | 1996-11-27 | 2004-08-31 | Aventis Pharm Prod Inc | A pharmaceutical preparation containing a component having an Xa antagonist activity and an antifouling agent |
| WO1998058902A1 (en) | 1997-06-23 | 1998-12-30 | Tanabe Seiyaku Co., Ltd. | INHIBITORS OF α4β1MEDIATED CELL ADHESION |
| ID26082A (id) | 1998-03-19 | 2000-11-23 | Briston Myers Squib Company | Sistem pengiriman lepas terkendali dwifasa untuk zat-zat farmasi kelarutan tinggi dan metodenya |
| US6685617B1 (en) | 1998-06-23 | 2004-02-03 | Pharmacia & Upjohn Company | Inhibitors of α4β1 mediated cell adhesion |
| US6339062B1 (en) * | 1998-11-23 | 2002-01-15 | Inkine Pharmaceutical Company, Inc. | Retroinverso polypeptides that mimic or inhibit thrombospondin activity |
| AU774185B2 (en) * | 1999-06-05 | 2004-06-17 | Board Of Trustees Of The Leland Stanford Junior University | Method and composition for inhibiting cardiovascular cell proliferation |
| EP1656945A1 (en) * | 1999-06-05 | 2006-05-17 | The Board Of Trustees Of The Leland Stanford Junior University | Pharmaceutical composition comprising oligoarginine |
| WO2005049647A2 (en) * | 2003-11-05 | 2005-06-02 | Pevion Biotech Ltd. | Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens |
| MX346362B (es) * | 2009-11-10 | 2017-03-15 | Allegro Pharmaceuticals Inc * | Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd. |
| EP2590634B1 (en) | 2010-07-09 | 2016-03-09 | BHV Pharma, Inc. | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4002602A (en) * | 1974-03-11 | 1977-01-11 | Gideon Goldstein | Ubiquitous immunopoietic polypeptide (UBIP) and methods |
| US4544500A (en) * | 1982-04-14 | 1985-10-01 | Scripps Clinic And Research Foundation | Synthetic foot and mouth disease antigen |
| DE3382031D1 (en) * | 1982-08-04 | 1991-01-10 | Jolla Cancer Res Found | Polypeptide. |
| US4578079A (en) * | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
-
1985
- 1985-10-28 US US06/791,872 patent/US4683291A/en not_active Expired - Fee Related
-
1986
- 1986-10-27 EP EP86308335A patent/EP0220957A3/en not_active Ceased
- 1986-10-27 CA CA000521502A patent/CA1306581C/en not_active Expired - Fee Related
- 1986-10-28 JP JP61259566A patent/JPS62161800A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62161800A (ja) | 1987-07-17 |
| AU597006B2 (en) | 1990-05-24 |
| AU6440786A (en) | 1987-04-30 |
| EP0220957A3 (en) | 1988-08-24 |
| US4683291A (en) | 1987-07-28 |
| US4683291B1 (enExample) | 1990-07-03 |
| EP0220957A2 (en) | 1987-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1306581C (en) | Platelet binding inhibitors | |
| CA1315479C (en) | Platelet-aggregation inhibitor peptide derivatives | |
| Kloczewiak et al. | Platelet receptor recognition domain on the. gamma. chain of human fibrinogen and its synthetic peptide analogues | |
| EP0422938B1 (en) | Fibrinogen receptor antagonists | |
| US5100875A (en) | Novel peptides having plateler aggregation inhibitory activity | |
| ES2097150T5 (es) | Inhibidores de agregacion plaquetaria. | |
| US5023233A (en) | Fibrinogen receptor antagonists | |
| CA2129339C (en) | Inhibitors of thrombosis | |
| US5374622A (en) | Fibrinogen receptor antagonists | |
| AU625801B2 (en) | Novel inhibitors of platelet binding | |
| US5061693A (en) | Fibrinogen receptor antagonists | |
| EP0410537A1 (en) | Fibrinogen receptor antagonists | |
| EP0410540A1 (en) | Fibrinogen receptor antagonists | |
| JPH03118332A (ja) | フイブリノーゲン受容体拮抗薬 | |
| US5498601A (en) | Platelet aggregation-inhibiting peptides | |
| EP0410539A1 (en) | Fibrinogen receptor antagonists | |
| EP0382451A3 (en) | Viper venom polypeptides and variants | |
| CA2066047A1 (en) | Anti-thrombotic peptides and pseudopeptides | |
| AU679913B2 (en) | Stable polypeptide composition | |
| US5338723A (en) | Fibrinogen receptor antagonists | |
| CA2242385A1 (en) | Antithrombotic agents and methods of use | |
| Yamamoto et al. | The Dansyl Group as a Molecular Probe for the Histochemical Localization of a Synthetic Fibronectin-related Peptide. | |
| CA2021953A1 (en) | Fibrinogen receptor antagonists | |
| CA2021949A1 (en) | Fibrinogen receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |